Allos Therapeutics Invites Investors to Listen to Webcast of Presentation at J.P. Morgan Healthcare Conference
21 Décembre 2011 - 2:00PM
Business Wire
Allos Therapeutics, Inc. (NASDAQ: ALTH), a biopharmaceutical
company committed to the development and commercialization of
innovative anti-cancer therapeutics, today announced that members
of the Company’s senior management will present at the 30th Annual
J.P. Morgan Healthcare Conference. Management will provide an
overview of the Company, including a commercial update for FOLOTYN®
(pralatrexate injection) for patients with relapsed or refractory
peripheral T-cell lymphoma.
The presentation will begin at 10:00 a.m. Pacific Time on
Wednesday, January 11, 2012. There will be a live webcast of the
presentation, which will be accessible through a link available on
the home page and investor relations section of the Allos website.
In addition, the webcast will be archived for 90 days.
About Allos Therapeutics
Allos Therapeutics, Inc. (Nasdaq: ALTH) is a biopharmaceutical
company committed to the development and commercialization of
innovative anti-cancer therapeutics. Allos is currently focused on
the development and commercialization of FOLOTYN® (pralatrexate
injection), a folate analogue metabolic inhibitor. FOLOTYN is
approved in the U.S. for the treatment of patients with relapsed or
refractory PTCL. For additional information, please visit
www.allos.com.
Safe Harbor Statement
The anticipated presentation will contain forward-looking
statements that involve significant risks and uncertainties.
Additional information concerning these forward-looking statements
and other factors that may cause actual results to differ
materially from those anticipated in the forward-looking statements
is contained in the "Risk Factors" section of the Company's
Quarterly Report on Form 10-Q for the quarter ended September 30,
2011 and in the Company's other periodic reports and filings with
the Securities and Exchange Commission. The Company cautions
investors not to place undue reliance on the forward-looking
statements contained in the presentation. All forward-looking
statements are based on information currently available to the
Company on the date thereof, and the Company undertakes no
obligation to revise or update these forward-looking statements to
reflect events or circumstances after the date of these
presentations, except as required by law.
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024
Real-Time news about Allos Therapeutics, Inc. (MM) (NASDAQ): 0 recent articles
Plus d'articles sur Allos Therapeutics